Patient info Search Menu

TELFAST 180 mg film-coated tablets – patient leaflet, side effects, dosage

Updated:
Key facts
Status:
Prescription only (POM)
Medicine strength:
180 mg
Other strengths and forms:
Contains active substance:

Patient leaflet - Telfast 180 mg film-coated tablets

1. What Telfast is and what it is used for

Telfast contains fexofenadine hydrochloride, which is a non-drowsy antihistamine.

Telfast 180 mg is used in adults and adolescents of 12 years and older to relieve the symptoms that occur with long term allergic skin reactions (chronic idiopathic urticaria) such as itching, swelling and rashes.

2. What you need to know before you take Telfast

Do not take Telfast

if you are allergic to fexofenadine or any of the other ingredients of this medicine (listed in section 6)

Warnings and precautions

Talk to your doctor or pharmacist before taking Telfast if: you have problems with your liver or kidneys you have or ever had heart disease, since this kind of medicine may lead to a fast or irregular heart beat you are elderly

If any of these apply to you, or if you are not sure, tell your doctor before taking Telfast.

Other medicines and Telfast

Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines. Indigestion remedies containing aluminium and magnesium may affect the action of Telfast by lowering the amount of medicinal product absorbed.

It is recommended that you leave about 2 hours between the time that you take Telfast and your indigestion remedy. Pregnancy and breast-feeding

Ask your doctor or pharmacist for advice before taking any medicine.

Do not take Telfast if you are pregnant, unless necessary. Telfast is not recommended during breast-feeding.

Driving and using machines

Telfast is unlikely to affect your ability to drive or operate machinery. However, you should check that these tablets do not make you feel sleepy or dizzy before driving or operating machinery.

3. How to take Telfast

Always take this medicine exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure. For adults and children aged 12 years and over

The recommended dose is one tablet (180 mg) daily. Take your tablet with water before a meal.

This medicine starts to relieve your symptoms within 1 hour and lasts for 24 hours.

If you take more Telfast than you should

If you take too many tablets, contact your doctor or the nearest hospital emergency department immediately. Symptoms of an overdose in adults are dizziness, drowsiness, fatigue and dry mouth.

If you forget to take Telfast

Do not take a double dose to make up for a forgotten tablet. Take the next dose at the usual time as prescribed by your doctor. If you stop taking Telfast

Tell your doctor if you want to stop taking Telfast before you have finished your course of treatment.

If you stop taking Telfast earlier than planned, your symptoms may return.

If you have any further questions on the use of this medicine, ask your doctor or pharmacist.

4. Possible side effects

Like all medicines, this medicine can cause side effects, although not everybody gets them.

Tell your doctor immediately and stop taking Telfast if you experience:

  • swelling of the face, lips, tongue or throat and difficulty breathing, as these may be signs of a serious allergic reaction.

0800 035 2525

The following undesirable effects have been reported in clinical trials, with an incidence similar to those observed in patient who did not receive the drug (placebo). Common side effects (may affect up to 1 in 10 people): - headache

  • drowsiness
  • feeling sick (nausea)
  • dizziness.

Uncommon side effects (may affect up to 1 in 100 people): - tiredness

  • sleepiness.

Additional side effects (frequency not known: cannot be estimated from the available data) which may occur are: - difficulty sleeping (insomnia)

  • sleeping disorders
  • bad dreams
  • nervousness
  • fast or irregular heart beat
  • diarrhoea
  • skin rash and itching
  • hives
  • serious allergic reactions which can cause swelling of the face, lips, tongue or throat, flushing, chest tightness, and difficulty breathing.

Reporting of side effects

If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet.

You can also report side effects directly via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. By reporting side effects you can help provide more information on the safety of this medicine.

5. How to store Telfast

Keep this medicine out of the sight and reach of children. Do not use this medicine after the expiry date which is stated on the carton after EXP. The expiry date refers to the last day of that month.

This medicine does not require any special storage condition. Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.

6. Contents of the pack and other information

What Telfast 180 mg contains

  • The active substance is fexofenadine hydrochloride. Each tablet contains 180 mg of fexofenadine hydrochloride. ● The other ingredients are:

    ○ Tablet core: microcrystalline cellulose, pregelatinised maize starch, croscarmellose sodium, magnesium stearate.

    ○ Film coating: hypromellose, povidone, titanium dioxide (E171), colloidal anhydrous silica, macrogol 400 and iron oxide (E172).

    What Telfast 180 mg looks like and contents of the pack

    Telfast 180 mg film-coated tablets are peach coloured, capsule shaped tablets marked with “018” on one side and a scripted “e” on the other.

    Telfast is presented in blister packs. Each tablet is blistered. Telfast is available in packs of 2 (sample only), 10, 15, 20, 30, 50, 100 and 200 (as 10x20) tablets per package. Not all pack sizes are marketed.

    Marketing Authorisation Holder:

    Sanofi, 410 Thames Valley Park Drive

    Reading, Berkshire, RG6 1PT, UK

    Tel: 0800 035 2525

    email: uk-medicalinformation@sanofi.com

    Manufacturer

    Sanofi Winthrop industrie,

    30-36 Avenue Gustave Eiffel,

    37100 Tours, France

    This medicinal product is authorised in the Member States of the EEA under the following names:

    Belgium: Telfast 180 mg filmomhulde tabletten Denmark: Telfast, filmovertrukne tabletter 180 mg Finland: Telfast 180 mg tabletti, kalvopäällysteinen Germany: Telfast 180 mg

    Ireland: Telfast 180 mg film coated tablets

    Italy: Telfast 180 mg compresse rivestite con film Luxembourg: Telfast 180 mg filmomhulde tabletten Malta: Telfast 180 mg film-coated tablets

    Portugal: Telfast 180, comprimidos revestidos por película Spain: Fexofenadina Sanofi 180 mg comprimidos recubiertos con película

    Sweden: Telfast 180 mg filmdragerade tabletter United Kingdom: Telfast 180 mg film coated tablets This leaflet was last revised in 06/2021.

    © Sanofi, 1996 – 2021

    809788

About this document

Source: MHRA - Medicines and Healthcare products Regulatory Agency (products.mhra.gov.uk)

Last revision stated in the text: June 2021

What the sections and the side effect frequencies mean: How to read a patient leaflet

Found a mistake? Tell us on the contact page.

The information on this site does not replace the advice of a doctor or pharmacist.

Facts about Telfast 180 mg film-coated tablets

What these facts mean

Prescription needed?? Yes, prescription-only medicine (POM)
Active substance? Fexofenadine
Strength? 180 mg
Pharmaceutical form? Oral tablet
Peach, capsule-shaped, film-coated tablet debossed with “018” on one side and a scripted “e” on the other side.
How is it taken? Oral
Excipients? Microcrystalline Cellulose, Pregelatinised Maize Starch, Croscarmellose Sodium, Magnesium Stearate, Hypromellose, Povidone, Titanium Dioxide (E171), Colloidal Anhydrous Silica, Macrogol 400, Iron oxide (E172)
Pack sizes 30 tablet
Is it available?? Listed as available (NHS Dictionary of Medicines and Devices – not a record of current supplies)
Shelf life? 3 years
Storage This medicinal product does not require any special storage conditions.
Drug group (ATC)? Antihistamines for systemic use
  1. R Respiratory system drugs
    1. R06 Antihistamines for systemic use
      1. R06A Antihistamines for systemic use
        1. R06AX Other antihistamines for systemic use
          1. R06AX26 fexofenadine
Marketing authorisation? PL 61186/0004 (first authorised 4 December 1996)
Marketing authorisation holder? Opella POM UK Limited, trading as Opella
Codes? GTIN 5015265300333 · BNF 03040100

Sources: the MHRA product information (products.mhra.gov.uk) and the NHS Dictionary of Medicines and Devices (dm+d), release 11.1.0 of 9 November 2026, NHS Business Services Authority. Contains public sector information licensed under the Open Government Licence v3.0.